Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of LY2216684 as adjunctive treatment for major depressive disorder
jRCT2080221483Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edivoxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started Jun 2011; status: recruiting.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221483.